ESMO 2018 | Updates on the CRISP study

Frank Griesinger, MD, PhD, of the University of Göttingen, Göttingen, Germany, discusses first results from the prospective German registry CRISP study, which includes 150 German centers encompassing nearly 3000 patients. Current data suggests a very high quality of life return in non small cell lung carcinoma (NSCLC) patients on pembrolizumab, but results from the study indicate that a significant proportion of patient candidates in Germany, eligible to receive pembrolizumab after determination of the underlying PD-L1 alteration, are not administered the treatment. The study highlights areas of testing and treatment stratification approaches where improvements are needed. This interview was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.